Evolus (NASDAQ:EOLS) Posts Quarterly Earnings Results

Evolus (NASDAQ:EOLS) issued its quarterly earnings data on Wednesday. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.09), reports. The company had revenue of $61.09 million during the quarter, compared to analysts’ expectations of $62.81 million. Evolus updated its FY 2024 guidance to EPS.

Evolus Price Performance

NASDAQ:EOLS traded down $0.60 during trading hours on Friday, reaching $13.69. 372,754 shares of the company traded hands, compared to its average volume of 584,401. Evolus has a 1-year low of $7.74 and a 1-year high of $17.82. The firm’s 50-day moving average is $16.26 and its 200-day moving average is $13.83. The company has a debt-to-equity ratio of 6.26, a current ratio of 2.92 and a quick ratio of 2.67. The stock has a market cap of $863.70 million, a P/E ratio of -15.70 and a beta of 1.31.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Barclays raised their target price on Evolus from $16.00 to $20.00 and gave the stock an “overweight” rating in a report on Friday, September 13th. Needham & Company LLC reiterated a “buy” rating and set a $22.00 price objective on shares of Evolus in a research report on Friday, September 13th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Evolus in a research report on Monday, September 16th. Finally, HC Wainwright reissued a “buy” rating and set a $27.00 target price on shares of Evolus in a research note on Thursday.

Insider Transactions at Evolus

In other Evolus news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the firm’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $15.85, for a total value of $89,251.35. Following the transaction, the chief marketing officer now directly owns 82,375 shares of the company’s stock, valued at $1,305,643.75. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Evolus news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of Evolus stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $15.85, for a total value of $89,251.35. Following the completion of the transaction, the chief marketing officer now directly owns 82,375 shares in the company, valued at $1,305,643.75. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Sandra Beaver sold 3,276 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $14.98, for a total value of $49,074.48. Following the transaction, the chief financial officer now owns 148,502 shares of the company’s stock, valued at approximately $2,224,559.96. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 6.10% of the company’s stock.

Hedge Funds Weigh In On Evolus

Institutional investors and hedge funds have recently modified their holdings of the stock. Oppenheimer & Co. Inc. acquired a new position in Evolus during the 3rd quarter worth $212,000. GSA Capital Partners LLP grew its stake in Evolus by 335.3% during the third quarter. GSA Capital Partners LLP now owns 120,964 shares of the company’s stock worth $1,960,000 after buying an additional 93,176 shares during the last quarter. Rice Hall James & Associates LLC grew its stake in shares of Evolus by 6.3% during the third quarter. Rice Hall James & Associates LLC now owns 904,900 shares of the company’s stock valued at $14,659,000 after purchasing an additional 53,605 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Evolus by 65.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 12,135 shares of the company’s stock valued at $197,000 after purchasing an additional 4,780 shares during the last quarter. Finally, Semanteon Capital Management LP bought a new position in Evolus in the third quarter valued at approximately $912,000. 90.69% of the stock is currently owned by hedge funds and other institutional investors.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.